QQ客服 官方微博 反馈留言

	Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4)
	Hu, C. S.; Chan, A.; Gao, L.; Ahn, M.J.; Cohen, E.; Ang, M.K.; Cheng, Y.; Hu, Q.; Kim, S.B.; Li, P.
	2015
卷号	26页码:100-100
ISSN号	0923-7534
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6663638
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Hu, C. S.,Chan, A.,Gao, L.,et al. Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4)[J],2015,26:100-100.
APA	Hu, C. S..,Chan, A..,Gao, L..,Ahn, M.J..,Cohen, E..,...&Wang, C.H..(2015).Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4).,26,100-100.
MLA	Hu, C. S.,et al."Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4)".26(2015):100-100.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。